Financial reports
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
22 Feb 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
18 Aug 22
NT 10-Q
Notice of late quarterly filing
15 Aug 22
10-Q
2022 Q1
Quarterly report
20 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
10-K
2021 FY
Annual report
7 Apr 22
NT 10-K
Notice of late annual filing
31 Mar 22
Current reports
8-K
Completion of Acquisition or Disposition of Assets
23 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
22 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Aug 23
8-K
Other Events
15 Aug 23
8-K
Pyxis Oncology to Acquire Apexigen
24 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Apr 23
8-K
Apexigen Announces Review of Strategic Alternatives and Restructuring
27 Feb 23
8-K
Departure of Directors or Certain Officers
14 Feb 23
8-K
Unregistered Sales of Equity Securities
1 Feb 23
8-K
Apexigen Announces Approximately $2.8 Million
25 Jan 23
Registration and prospectus
15-12G
Securities registration termination
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Aug 23
25-NSE
Exchange delisting
23 Aug 23
425
Business combination disclosure
11 Aug 23
425
Business combination disclosure
11 Aug 23
425
Business combination disclosure
30 Jun 23
425
Business combination disclosure
25 May 23
425
Business combination disclosure
24 May 23
425
Business combination disclosure
24 May 23
425
Business combination disclosure
24 May 23
Other
EFFECT
Notice of effectiveness
10 Apr 23
EFFECT
Notice of effectiveness
10 Apr 23
EFFECT
Notice of effectiveness
22 Mar 23
CORRESP
Correspondence with SEC
20 Mar 23
EFFECT
Notice of effectiveness
12 Sep 22
EFFECT
Notice of effectiveness
12 Sep 22
CORRESP
Correspondence with SEC
8 Sep 22
CORRESP
Correspondence with SEC
8 Sep 22
CORRESP
Correspondence with SEC
1 Sep 22
CORRESP
Correspondence with SEC
1 Sep 22